Practice guidelines for prenatal and perinatal immunohematology, revisited

Judd, W. John

doi:10.1046/j.1537-2995.2001.41111445.x

Cited by 104 publications

(145 citation statements)

References 36 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Care must be given to adequately sterilize the field prior to obtaining blood cultures just as when obtaining blood cultures from other sites. Neonatal blood type and screen is widely accepted when obtained from umbilical cord blood [26,27]. Some states recommend drawing the newborn metabolic screening tests of VLBW infants before antibiotics are started, blood products are transfused or amino acid-containing hyperalimentation solutions are administered, and in many cases this is upon admission to the NICU.…”

Section: Rbc Transfusionmentioning

confidence: 99%

Evidence-Based Advances in Transfusion Practice in Neonatal Intensive Care Units

2014

View full text Add to dashboard Cite

Background: Transfusions to neonates convey both benefits and risks, and evidence is needed to guide wise use. Such evidence is accumulating, but more information is needed to generate sound evidence-based practices. Objective: We sought to analyze published information on nine aspects of transfusion practice in neonatal intensive care units. Methods: We assigned ‘categories of evidence' and ‘recommendations' using the format of the United States Preventive Services Task Force of the Agency for Healthcare Research and Quality. Results: The nine practices studied were: (1) delayed clamping or milking of the umbilical cord at preterm delivery - recommended, high/substantial A; (2) drawing the initial blood tests from cord/placental blood from very low birth weight (VLBW, <1,500 g) infants at delivery - recommended, moderate/moderate B; (3) limiting phlebotomy losses of VLBW infants - recommended, moderate/substantial B; (4) selected use of erythropoiesis-stimulating agents to prevent transfusions - recommended, moderate/moderate-moderate/small B, C; (5) using platelet mass, rather than platelet count, in platelet transfusion decisions - recommended, moderate/small C; (6) permitting the platelet count to fall to <20,000/µl in ‘stable' neonates before transfusing platelets - recommended, low/small I; (8) permitting the platelet count to fall to <50,000/µl in ‘unstable' neonates before transfusing platelets - recommended, moderate/small C, and (9) not performing routine coagulation test screening on every VLBW infant - recommended, moderate/small C. Conclusions: We view these recommendations as dynamic, to be revised as additional evidence becomes available. We predict this list will expand as new studies provide more information to guide best transfusion practices.

show abstract

Section: Rbc Transfusionmentioning

confidence: 99%

Evidence-Based Advances in Transfusion Practice in Neonatal Intensive Care Units

2014

View full text Add to dashboard Cite

show abstract

“…9 During each pregnancy, all women should be tested for clinically significant unexpected serum antibodies, preferably at their first visit to the obstetrician. 10 If this initial antibody screen is negative, it is highly unlikely that a Rh-negative parturient would convert to a positive antibody screen due to antibodies other than anti-D, unless there was a history of blood transfusions in the interim. A retrospective review of 17,568 pregnancies by Heddle, et al 11 found 42 cases (0.24%) in which new antibody production occurred during pregnancy with no clinically significant neonatal sequelae occurring due to the newly formed antibodies.…”

Section: Discussionmentioning

confidence: 99%

A retrospective study of positive antibody screens at delivery in Rh-negative parturients

Cambic

Scavone

McCarthy

et al. 2010

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

Purpose Rhesus-(Rh-) negative women receiving anti-D antibodies antenatally often have a positive antibody screen at delivery. We investigated the incidence of positive antibody screens at delivery in this population and examined how the presence of positive antibody screens affected the time required to obtain type and screen or type and crossmatch results. Methods Records of parturients who had type and screen or type and crossmatch done upon presentation for delivery from June to October 2007 were examined to determine estimated gestational age at admission, Rh-status, the presence of positive antibody screens, and the time interval from receipt of specimen in the blood bank to the availability of antibody screen results. Results Of the 480 specimens sent for type and screen or type and crossmatch, 20% of parturients were Rh-negative, with 57% of those demonstrating a positive antibody screen compared with 4% of the Rh-positive parturients (P \ 0.01). In the Rh-negative group, 100% (95% CI 98-102) of positive antibody screens were anti-D antibodies. There was a longer median laboratory time for Rh-negative vs Rh-positive parturients (146 vs 65 min), for antibody positive vs antibody negative parturients (243 vs 65 min) (P \ 0.001 for both), but not for Rh-positive/antibody positive vs Rh-negative/antibody positive patients (312 vs 218 min) (P = 0.09). The antibody screen was positive in 100% of Rh-negative parturients until 37 weeks gestation, after which there was a decline. Conclusions Rh-negative parturients who receive anti-D antibodies antenatally have a higher incidence of positive antibody screens at delivery than Rh-positive parturients due to the presence of anti-D antibodies.

show abstract

“…placental evacuation to be sure that all the foetal erythrocytes have entered in maternal circulation [30].…”

Section: Detection Of Foetal Erythrocytesmentioning

confidence: 99%

Anti-D Prophylaxis Reviewed in the Erea of Foetal RHD Genotyping

Minon¹,

Gerard²,

Chantraine

et al. 2015

J Blood Disord Transfus

View full text Add to dashboard Cite

A few years ago, the prevention of anti-D immunization was currently based on systematic postnatal prophylaxis associated with targeted antenatal injection in high-risk situations of foeto-maternal haemorrhage. The failures of prevention are mainly due to the non-respect of established guidelines for RhIG prophylaxis, and to spontaneous undetected foetal-maternal haemorrhages without any obvious cause during the third trimester of pregnancy.In order to reduce the rate of residual post-pregnancy anti-D immunization, several countries decided to associate the classical prophylaxis to a routine antenatal anti-D prophylaxis (RAADP) during the 28th or 29th week of gestation. Since about ten years, the foetal RHD genotyping in maternal plasma enables us to limit the antenatal prophylaxis only to those D-women carrying a D+ foetus. This paper deals with: the advantages of an antenatal prevention in the light of non invasive foetal RHD genotyping, the rules rendering prevention protocols efficient whatever the algorithm applied, and the recommended immuno-haematology follow-up of women who have received RhIG.

show abstract

Practice guidelines for prenatal and perinatal immunohematology, revisited

Cited by 104 publications

References 36 publications

Evidence-Based Advances in Transfusion Practice in Neonatal Intensive Care Units

Evidence-Based Advances in Transfusion Practice in Neonatal Intensive Care Units

A retrospective study of positive antibody screens at delivery in Rh-negative parturients

Anti-D Prophylaxis Reviewed in the Erea of Foetal RHD Genotyping

Contact Info

Product

Resources

About